AGIO Agios Pharmaceuticals, Inc.
Healthcare$28.12+0.00%OpenMarket Cap: $1.67B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
25.34
EV/EBITDA
-3.39
DCF Value
$-26.44
FCF Yield
-23.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.1%
Operating Margin
-720.0%
Net Margin
-639.8%
ROE
-34.1%
ROA
-35.7%
ROIC
-41.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.7M | 87.1% | $-110.0M | $-99.1M | $— | — |
| Q4 null | $20.0M | 84.2% | $-121.6M | $-108.0M | $— | — |
| FY null | $54.0M | 78.7% | $-472.1M | $-412.8M | $— | — |
| Q3 null | $12.9M | 76.3% | $-116.9M | $-103.4M | $— | — |
| Q2 null | $12.5M | 76.2% | $-127.1M | $-112.0M | $— | — |
| Q1 null | $8.7M | 72.9% | $-106.6M | $-89.3M | $— | — |
| Q4 null | $10.7M | 88.3% | $-125.0M | $-96.5M | $— | — |
| FY null | $36.5M | 88.6% | $-425.7M | $673.7M | $— | — |
| Q3 null | $9.0M | 91.3% | $-102.8M | $947.9M | $— | — |
| Q2 null | $8.6M | 64.2% | $-105.8M | $-96.1M | $— | — |
| Q1 null | $8.2M | 75.9% | $-92.1M | $-81.5M | $— | — |
| Q4 2023 | $7.1M | 72.0% | $-106.3M | $-95.9M | $-1.72 | — |